Compare Stocks: TRIL, BLU, AUP, and ONC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUP Aurinia Pharmaceuticals		C$0.00	C$11.77 ▼ C$26.00	C$2.15B	N/A	229,895 shs	4.61 million shs
BLU BELLUS Health		C$0.00	C$8.58 ▼ C$19.90	C$2.47B	-0.28	59,471 shs	28,666 shs
ONC BeOne Medicines	$362.51 +4.3%	$306.30	$253.95 ▼ $385.22	$38.15B	0.49	408,925 shs	465,416 shs
TRIL Defiance Trillion Dollar Club Index ETF	$19.86	$18.12	$5.80 ▼ $20.96	$2.09B	2.08	1.87 million shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUP Aurinia Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BLU BELLUS Health	0.00%	0.00%	0.00%	0.00%	0.00%
ONC BeOne Medicines	0.00%	-0.23%	+11.36%	+18.56%	+8.13%
TRIL Defiance Trillion Dollar Club Index ETF	0.00%	0.00%	0.00%	0.00%	+7.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUP Aurinia Pharmaceuticals		C$0.00	C$11.77 ▼ C$26.00	C$2.15B	N/A	229,895 shs	4.61 million shs
BLU BELLUS Health		C$0.00	C$8.58 ▼ C$19.90	C$2.47B	-0.28	59,471 shs	28,666 shs
ONC BeOne Medicines	$362.51 +4.3%	$306.30	$253.95 ▼ $385.22	$38.15B	0.49	408,925 shs	465,416 shs
TRIL Defiance Trillion Dollar Club Index ETF	$19.86	$18.12	$5.80 ▼ $20.96	$2.09B	2.08	1.87 million shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUP Aurinia Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BLU BELLUS Health	0.00%	0.00%	0.00%	0.00%	0.00%
ONC BeOne Medicines	0.00%	-0.23%	+11.36%	+18.56%	+8.13%
TRIL Defiance Trillion Dollar Club Index ETF	0.00%	0.00%	0.00%	0.00%	+7.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUP Aurinia Pharmaceuticals	0.00	N/A	N/A	N/A
BLU BELLUS Health	0.00	N/A	N/A	N/A
ONC BeOne Medicines	3.00	Buy	$402.14	10.93% Upside
TRIL Defiance Trillion Dollar Club Index ETF	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TRIL, BLU, AUP, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	ONC BeOne Medicines	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$370.00
8/7/2026	ONC BeOne Medicines	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2026	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/6/2026	ONC BeOne Medicines	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	ONC BeOne Medicines	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$403.00 ➝ $407.00
8/6/2026	ONC BeOne Medicines	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$424.00 ➝ $454.00
8/6/2026	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$451.00 ➝ $450.00
8/6/2026	ONC BeOne Medicines	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$416.00 ➝ $418.00
8/6/2026	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$420.00 ➝ $430.00
8/6/2026	ONC BeOne Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$396.00 ➝ $405.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUP Aurinia Pharmaceuticals	C$57.59M	0.00	N/A	6.75	C$2.59 per share	0.00
BLU BELLUS Health	C$16K	0.00	N/A	4.67	C$2.91 per share	0.00
ONC BeOne Medicines	$5.34B	7.45	$4.08 per share	88.90	$39.77 per share	9.12
TRIL Defiance Trillion Dollar Club Index ETF	$150K	13,903.44	N/A	N/A	$2.56 per share	7.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUP Aurinia Pharmaceuticals	N/A	-C$1.48	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BLU BELLUS Health	-C$86.79M	-C$0.96	N/A	N/A	N/A	N/A	-26.76%	-16.70%	N/A
ONC BeOne Medicines	$286.93M	$5.68	63.82	26.60	N/A	10.70%	14.23%	7.82%	N/A
TRIL Defiance Trillion Dollar Club Index ETF	-$59.35M	$0.62	32.04	N/A	N/A	N/A	-23.31%	-18.66%	N/A

Latest TRIL, BLU, AUP, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2026	Q2 2026	ONC BeOne Medicines	$1.40	$2.05	+$0.65	$2.05	$1.66 billion	$1.71 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUP Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BLU BELLUS Health	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
TRIL Defiance Trillion Dollar Club Index ETF	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUP Aurinia Pharmaceuticals	2.69	11.93	11.02
BLU BELLUS Health	0.32	33.42	16.40
ONC BeOne Medicines	0.17	3.40	3.06
TRIL Defiance Trillion Dollar Club Index ETF	N/A	19.82	19.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUP Aurinia Pharmaceuticals	N/A
BLU BELLUS Health	90.41%
ONC BeOne Medicines	48.55%
TRIL Defiance Trillion Dollar Club Index ETF	87.15%

Insider Ownership

Company	Insider Ownership
AUP Aurinia Pharmaceuticals	N/A
BLU BELLUS Health	10.26%
ONC BeOne Medicines	6.19%
TRIL Defiance Trillion Dollar Club Index ETF	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUP Aurinia Pharmaceuticals	300	128.40 million	N/A	Not Optionable
BLU BELLUS Health	74	126.81 million	N/A	Not Optionable
ONC BeOne Medicines	12,000	109.79 million	102.99 million	N/A
TRIL Defiance Trillion Dollar Club Index ETF	33	105.00 million	95.44 million	No Data

TRIL, BLU, AUP, and ONC Headlines

Recent News About These Companies

The Trillion-Dollar Club: Mega-Cap Stocks With Market Caps Over $1 Trillion

June 17, 2026 | money.usnews.com

ETF Prime: Murphy on the New Faces of the ETF Boom

October 29, 2025 | etftrends.comE

Defiance Trillion Dollar Club Index ETF

October 21, 2025 | money.usnews.com

Tidal Trust II - Defiance Trillion Dollar Club Index ETF

October 16, 2025 | money.usnews.com

Trillion-Dollar Inflows: ETFs Become the Market’s New “Pulse”

October 16, 2025 | nai500.comN

The Future Of Psychedelic-Inspired Therapeutics: No-Trip Neuroplastogens

August 14, 2025 | lifescienceleader.comL

Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problems

July 1, 2025 | biospace.comB

Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted Radiotherapeutics

June 20, 2025 | finance.yahoo.com

Trillium Therapeutics Stock Price History

May 26, 2025 | investing.com

TTI Consumer Power Tools, Inc. is Seeking an IP Paralegal

September 26, 2024 | ipwatchdog.comI

Advances in Drug Discovery & Development 2024

September 8, 2024 | technologynetworks.comT

When You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) Stock

July 30, 2024 | finance.yahoo.com

Google Cloud unveils the Trillium TPU, its most powerful AI processor so far

May 14, 2024 | siliconangle.comS

Cachet Bicycle shakes off COVID

February 25, 2024 | baytoday.caB

Rejuvenate your look with a trip to Fourth Avenue Medical Aesthetics

January 30, 2024 | chch.comC

TTI apprehends motorists for illegal removal of clamps, hunt for four others underway

January 30, 2024 | bulawayo24.comB

BridgeBio raises $1.25bn, and other biotech financings

January 19, 2024 | pharmaphorum.comP

Ratio Therapeutics Raises $50M in Series B Financing

January 17, 2024 | precisionmedicineonline.comP

Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com

November 10, 2023 | businesswire.com

Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions

November 8, 2023 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TRIL, BLU, AUP, and ONC Company Descriptions

Aurinia Pharmaceuticals TSE:AUP

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

BELLUS Health TSE:BLU

BluEnergies Ltd. is a Canadian based oil and gas exploration and development company focused on offshore West Africa. The Company has recently partnered with TotalEnergies to explore its basin floor fan plays in Blocks LB-26, LB-30, and LB-31 covering an area of approximately 8,924 square kilometers (~2.2 million acres) located in the Harper Basin, in the deep-water offshore Liberia. Additionally, the Company recently acquired a previously discovered and tested sand channel play offshore Louisiana in the shallow water Gulf of America.

BeOne Medicines NASDAQ:ONC

$362.51 +15.03 (+4.33%)

As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Defiance Trillion Dollar Club Index ETF NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRIL, BLU, AUP, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRIL, BLU, AUP, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRIL, BLU, AUP, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TRIL, BLU, AUP, and ONC Company Descriptions

Aurinia Pharmaceuticals TSE:AUP

BELLUS Health TSE:BLU

BeOne Medicines NASDAQ:ONC

Defiance Trillion Dollar Club Index ETF NASDAQ:TRIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRIL, BLU, AUP, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRIL, BLU, AUP, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRIL, BLU, AUP, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TRIL, BLU, AUP, and ONC Company Descriptions

Aurinia Pharmaceuticals TSE:AUP

BELLUS Health TSE:BLU

BeOne Medicines NASDAQ:ONC

Defiance Trillion Dollar Club Index ETF NASDAQ:TRIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools